What are the main indications of guselkumab and its mechanism of action?

Guselkumab (Guselkumab) is a fully human IgG1 monoclonal antibody, mainly used to treat moderate to severe plaque psoriasis (Plaque Psoriasis) and patients with active psoriatic arthritis (Psoriatic Arthritis). It targets the p19 subunit of interleukin 23 (IL-23), thereby blocking the IL-23/Th17 inflammatory pathway, which is one of the key mechanisms in the pathogenesis of psoriasis. IL-23promotes Th17 cells to secrete IL-17 and IL-22. These cytokines can stimulate excessive proliferation of keratinocytes and inflammatory responses. Guselkumab inhibits the inflammatory cascade from the source by blocking IL-23 signaling, reducing skin damage and improving joint symptoms. Clinical studies have shown that approximately 70%-80% of patients treated with guselkumab can achieve PASI within 16 weeks. 90 (Psoriasis area and severity index improvement 90%), showing strong and long-lasting efficacy.